Fig. 1

Kaplan-Meier analysis of (a) overall and (b) relapse-free survival of patients who were treated with tegafur-uracil for LVI-positive stage IA NSCLC in adjuvant setting. Kaplan-Meier analysis of (c) overall and (d) relapse-free survival of patients who were treated with tegafur-uracil for 2 cm or less size LVI-positive stage IA NSCLC in adjuvant setting. LVI, lymphovascular invasion; NSCLC, non-small cell carcinoma